Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WILLIAM B EAVES

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1801861240
CMS profile
353833
Location
SHREVEPORT, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,944.54

78 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,944.54 78

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WILLIAM B EAVES

NPI 1801861240 · CMS profile ID 353833

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

SHREVEPORT, LA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1801861240?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WILLIAM B EAVES, NPI 1801861240, CMS profile ID 353833. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1801861240?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). WILLIAM B EAVES, NPI 1801861240, CMS profile ID 353833. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1801861240?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
WILLIAM B EAVES, NPI 1801861240, CMS profile ID 353833, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1801861240?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

78 matching records · $1,944.54 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 78 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–78 of 78.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boston Scientific Corporation $44.7405/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022375687 CMS
Boston Scientific Corporation $24.5805/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022187799 CMS
PFIZER INC. $14.8205/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049127005 CMS
E.R. Squibb & Sons, L.L.C. $16.2505/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016183049 CMS
ABIOMED $31.5605/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044645421 CMS
ABIOMED $130.0205/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044645501 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $16.3305/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 984118457 CMS
Boston Scientific Corporation $13.0704/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022179235 CMS
PFIZER INC. $0.3704/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049541051 CMS
PFIZER INC. $13.3304/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050361523 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $18.4104/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 984118469 CMS
ABIOMED $38.2704/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044645363 CMS
Merck Sharp & Dohme LLC $21.7403/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048824407 CMS
iRhythm Technologies, Inc. $158.3103/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059023619 CMS
Boston Scientific Corporation $25.9103/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022375683 CMS
Boston Scientific Corporation $73.0703/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022201275 CMS
PFIZER INC. $17.9403/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050396403 CMS
PFIZER INC. $2.1303/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050685013 CMS
Novartis Pharmaceuticals Corporation $15.9002/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991436091 CMS
Boston Scientific Corporation $13.9302/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022201269 CMS
PFIZER INC. $18.4002/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050702125 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.8002/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996840633 CMS
Merck Sharp & Dohme LLC $15.5802/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048561095 CMS
Boston Scientific Corporation $13.1702/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022245981 CMS
PFIZER INC. $19.1301/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050635029 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $15.0201/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 984118453 CMS
PFIZER INC. $15.9501/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050569073 CMS
AstraZeneca Pharmaceuticals LP $14.0101/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014439907 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5,700.91 105
PY2020 $850.09 36
PY2021 $1,231.08 59
PY2022 $2,213.99 83
PY2023 $1,944.54 78
PY2024 $1,188.49 61
PY2025 $2,244.56 90

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $266,424.24 186
PY2024 Principal investigator $357,755.26 62
PY2023 Principal investigator $224,921.66 95
PY2022 Principal investigator $145,582.14 143
PY2021 Recipient $24,674.00 1
PY2021 Principal investigator $209,373.41 222
PY2020 Recipient $4,050.00 5
PY2020 Principal investigator $153,906.98 70
PY2019 Recipient $10,000.00 3
PY2019 Principal investigator $245,623.21 96

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

186 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $22,000.00 12/19/2025 Non-covered Recipient Entity
PharmaSeek, LLC dba WCG Site Network
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220815151
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 12/17/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220714554
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 12/17/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220714564
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 12/17/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220714566
Principal investigator 1 Boehringer Ingelheim International GmbH $60.00 12/15/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714382
Principal investigator 1 Janssen Research & Development, LLC $79.00 12/12/2025 Non-covered Recipient Entity
Grace Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175223194
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $391.52 12/09/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220806475
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,669.24 12/04/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220996958
Principal investigator 1 AstraZeneca Pharmaceuticals LP $10,250.00 12/03/2025 Non-covered Recipient Entity
GRACE RESEARCH LLC
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event No dispute reported 06/30/2026 1185550499
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714378
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714380
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714536
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714538
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714540
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714542
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714544
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714546
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 12/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220714556
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 12/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220714558
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 12/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220714560
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220714562
Principal investigator 1 Boehringer Ingelheim International GmbH $259.00 11/19/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714374
Principal investigator 1 Boehringer Ingelheim International GmbH $2,843.00 11/19/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714376
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 11/19/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220806473
Principal investigator 1 Janssen Research & Development, LLC $4,822.00 11/19/2025 Non-covered Recipient Entity
Grace Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175223111
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,662.32 11/18/2025 Non-covered Recipient Entity
GRACE RESEARCH, LLC
Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION) No dispute reported 06/30/2026 1190313585
Principal investigator 1 Janssen Research & Development, LLC $3,702.00 11/07/2025 Non-covered Recipient Entity
Grace Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175223248
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714370
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714372
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714524
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714526
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714528
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714530
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714532
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714534
Principal investigator 1 Ionis Pharmaceuticals, Inc. $3,361.50 10/29/2025 Non-covered Recipient Entity
GRACE RESEARCH LLC
IS354CS15 No dispute reported 06/30/2026 1246789759
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714366
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714368
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714512
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714514
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714516
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714518
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714520
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714522
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 09/24/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714358
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 09/24/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714360
Principal investigator 1 Boehringer Ingelheim International GmbH $1.74 09/24/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714362
Principal investigator 1 Boehringer Ingelheim International GmbH $3.76 09/24/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714364
Principal investigator 1 Janssen Research & Development, LLC $956.00 09/19/2025 Non-covered Recipient Entity
Grace Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175223283
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714346
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714348
Principal investigator 1 Boehringer Ingelheim International GmbH $30.79 09/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714470
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714482
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714484
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714486
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714488
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714490
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714506
Principal investigator 1 Ionis Pharmaceuticals, Inc. $68.00 08/29/2025 Non-covered Recipient Entity
GRACE RESEARCH LLC
IS354CS6 No dispute reported 06/30/2026 1246787007
Principal investigator 1 Ionis Pharmaceuticals, Inc. $156.00 08/29/2025 Non-covered Recipient Entity
GRACE RESEARCH LLC
IS354CS6 No dispute reported 06/30/2026 1246787010
Principal investigator 1 Ionis Pharmaceuticals, Inc. $248.00 08/29/2025 Non-covered Recipient Entity
GRACE RESEARCH LLC
IS354CS6 No dispute reported 06/30/2026 1246787015
Principal investigator 1 Ionis Pharmaceuticals, Inc. $300.00 08/29/2025 Non-covered Recipient Entity
GRACE RESEARCH LLC
IS354CS6 No dispute reported 06/30/2026 1246787019
Principal investigator 1 Ionis Pharmaceuticals, Inc. $500.00 08/29/2025 Non-covered Recipient Entity
GRACE RESEARCH LLC
IS354CS6 No dispute reported 06/30/2026 1246787023
Principal investigator 1 Ionis Pharmaceuticals, Inc. $3,600.00 08/29/2025 Non-covered Recipient Entity
GRACE RESEARCH LLC
IS354CS6 No dispute reported 06/30/2026 1246787027
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 08/26/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714508
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 08/26/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714510
Principal investigator 1 Janssen Research & Development, LLC $1,020.00 08/25/2025 Non-covered Recipient Entity
Grace Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175223200
Principal investigator 1 Janssen Research & Development, LLC $5,160.00 08/21/2025 Non-covered Recipient Entity
GRACE RESEARCH LLC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175345788
Principal investigator 1 Boehringer Ingelheim International GmbH $216.00 08/20/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714354
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,050.00 08/19/2025 Non-covered Recipient Entity
GRACE RESEARCH LLC
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190309364
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $11,496.60 08/06/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220799467
Principal investigator 1 Ionis Pharmaceuticals, Inc. $6,336.90 08/06/2025 Non-covered Recipient Entity
GRACE RESEARCH LLC
IS354CS15 No dispute reported 06/30/2026 1246786175
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714342
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714344
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714472
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714474
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714476
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714478
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714480
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714504
Principal investigator 1 Boehringer Ingelheim International GmbH $219.78 07/28/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714356
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 07/28/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220714548
Principal investigator 1 Boehringer Ingelheim International GmbH $359.64 07/28/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220714550
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 07/28/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220714552
Principal investigator 1 Boehringer Ingelheim International GmbH $2,627.00 07/25/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714338
Principal investigator 1 Boehringer Ingelheim International GmbH $259.00 07/25/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714340
Principal investigator 1 Janssen Research & Development, LLC $510.00 07/23/2025 Non-covered Recipient Entity
Grace Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175223126
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714350
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714352
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714492
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714494
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714496
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714498
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714500
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714502
Principal investigator 1 Boehringer Ingelheim International GmbH $93.28 06/24/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714336
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 06/24/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714468
Principal investigator 1 Janssen Research & Development, LLC $718.00 06/23/2025 Non-covered Recipient Entity
Grace Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175223240
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 06/19/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220996956
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714330
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714332
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 06/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714454
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714456
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714458
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714460
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714462
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714464
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714466
Principal investigator 1 Janssen Research & Development, LLC $4,900.00 05/21/2025 Non-covered Recipient Entity
Grace Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175223163
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714326
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714328
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714442
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714444
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714446
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714448
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714450
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714452
Principal investigator 1 PFIZER INC. $374.40 04/26/2025 Non-covered Recipient Entity
Grace Research LLC
A LOWINTERVENTIONAL PROSPECTIVE LONGITUDINAL COHORT STUDY TO COLLECT DIGITAL FUNCTIONAL ASSESSMENTS AND EVALUATE SYMPTOMS IN STUDY PARTICIPANTS WITH CHRONIC HEART FAILURE No dispute reported 06/30/2026 1228794517
Principal investigator 1 Boehringer Ingelheim International GmbH $1.55 04/23/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714334
Principal investigator 1 Janssen Research & Development, LLC $2,450.00 04/23/2025 Non-covered Recipient Entity
Grace Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175223274
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714322
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714324
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714430
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714432
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714434
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714436
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714438
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714440
Principal investigator 1 Novartis Pharmaceuticals Corporation $24,668.87 03/31/2025 Non-covered Recipient Entity
GRACE RESEARCH, LLC
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190313583
Principal investigator 1 Boehringer Ingelheim International GmbH $23.32 03/25/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714422
Principal investigator 1 Boehringer Ingelheim International GmbH $511.00 03/25/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714424
Principal investigator 1 Boehringer Ingelheim International GmbH $12.18 03/25/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714426
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $17,649.90 03/25/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220799465
Principal investigator 1 PFIZER INC. $2,200.00 03/22/2025 Non-covered Recipient Entity
Grace Research LLC
A LOWINTERVENTIONAL PROSPECTIVE LONGITUDINAL COHORT STUDY TO COLLECT DIGITAL FUNCTIONAL ASSESSMENTS AND EVALUATE SYMPTOMS IN STUDY PARTICIPANTS WITH CHRONIC HEART FAILURE No dispute reported 06/30/2026 1228796379
Principal investigator 1 Boehringer Ingelheim International GmbH $338.00 03/19/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714308
Principal investigator 1 Boehringer Ingelheim International GmbH $3,523.00 03/19/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714310
Principal investigator 1 Boehringer Ingelheim International GmbH $2,681.00 03/19/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714312
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,188.00 03/12/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220799463
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714302
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714304
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714408
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714410
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714412
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714414
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714416
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714418
Principal investigator 1 PFIZER INC. $2,580.00 02/28/2025 Non-covered Recipient Entity
Grace Research LLC
A LOWINTERVENTIONAL PROSPECTIVE LONGITUDINAL COHORT STUDY TO COLLECT DIGITAL FUNCTIONAL ASSESSMENTS AND EVALUATE SYMPTOMS IN STUDY PARTICIPANTS WITH CHRONIC HEART FAILURE No dispute reported 06/30/2026 1228769059
Principal investigator 1 Boehringer Ingelheim International GmbH $159.00 02/25/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714294
Principal investigator 1 Boehringer Ingelheim International GmbH $1,473.00 02/25/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714296
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 02/25/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714316
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 02/25/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714318
Principal investigator 1 Boehringer Ingelheim International GmbH $9.40 02/25/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714320
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,899.64 02/25/2025 Non-covered Recipient Entity
GRACE RESEARCH, LLC
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190313587
Principal investigator 1 Janssen Research & Development, LLC $3,025.00 02/19/2025 Non-covered Recipient Entity
Grace Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175223217
Principal investigator 1 PFIZER INC. $6,450.00 02/05/2025 Non-covered Recipient Entity
Grace Research LLC
A LOWINTERVENTIONAL PROSPECTIVE LONGITUDINAL COHORT STUDY TO COLLECT DIGITAL FUNCTIONAL ASSESSMENTS AND EVALUATE SYMPTOMS IN STUDY PARTICIPANTS WITH CHRONIC HEART FAILURE No dispute reported 06/30/2026 1228750167
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714298
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714300
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714394
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714396
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714398
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714400
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714402
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714404
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714406
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 01/31/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714306
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,119.00 01/30/2025 Non-covered Recipient Entity
GRACE RESEARCH LLC
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190299989
Principal investigator 1 Eli Lilly and Company $17,244.00 01/28/2025 Non-covered Recipient Entity
GRACE RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187882806
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,600.00 01/28/2025 Non-covered Recipient Entity
GRACE RESEARCH LLC
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190299993
Principal investigator 1 Amgen Inc. $17,642.00 01/27/2025 Non-covered Recipient Entity
GRACE RESEARCH, LLC
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke No dispute reported 06/30/2026 1246641898
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 01/27/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714314
Principal investigator 1 Boehringer Ingelheim International GmbH $773.85 01/27/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714420
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,215.10 01/27/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220799461
Principal investigator 1 Boehringer Ingelheim International GmbH $1,473.00 01/24/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714286
Principal investigator 1 Boehringer Ingelheim International GmbH $2,041.00 01/24/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714288
Principal investigator 1 Janssen Research & Development, LLC $2,868.00 01/22/2025 Non-covered Recipient Entity
Grace Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175223257
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,515.60 01/17/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220799459
Principal investigator 1 PFIZER INC. $3,271.20 01/10/2025 Non-covered Recipient Entity
Grace Research LLC
A LOWINTERVENTIONAL PROSPECTIVE LONGITUDINAL COHORT STUDY TO COLLECT DIGITAL FUNCTIONAL ASSESSMENTS AND EVALUATE SYMPTOMS IN STUDY PARTICIPANTS WITH CHRONIC HEART FAILURE No dispute reported 06/30/2026 1228800117
Principal investigator 1 Eli Lilly and Company $1,986.03 01/08/2025 Non-covered Recipient Entity
GRACE RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187882042
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714290
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
Grace Research LLC
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220714292
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714384
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714386
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714388
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714390
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714392
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Grace Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220714428